Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2014

Open Access 01-12-2014 | Research article

A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia

Authors: AnnCatherine M Downing, Bruce J Kinon, Brian A Millen, Lu Zhang, Lin Liu, Margarita A Morozova, Ronald Brenner, Tami Jo Rayle, Laura Nisenbaum, Fangyi Zhao, Juan Carlos Gomez

Published in: BMC Psychiatry | Issue 1/2014

Login to get access

Abstract

Background

Pomaglumetad methionil (LY2140023 monohydrate) is a potent and highly selective agonist for the metabotropic glutamate mGluR2 and mGluR3 receptors. We present results of a pivotal clinical study H8Y-MC-HBBM assessing the efficacy of LY2140023 in improving symptoms as a monotherapy in patients with an acute exacerbation of schizophrenia.

Methods

Enrolled adult patients (ages 18–65) with schizophrenia who had experienced an exacerbation of symptoms within 2 weeks prior to study entry. Patients (N = 1013) were randomized 2:2:2:1 to treatment with placebo, LY40 mg twice daily (BID), LY80 mg BID, or risperidone (RIS) 2 mg BID for 6 weeks after a one-week blinded placebo lead-in. The primary outcome assessed change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score in an overall schizophrenia population and a predefined subpopulation which excluded non-Hispanic white patients with the A/A genotype at the HTR2A SNP rs7330461.

Results

Neither LY2140023 dose showed significant improvement compared to placebo on PANSS total in either population (1-sided p-value [significance level], overall: LY40, p = .154 [0.01]; LY80, p = .698 [0.01], subpopulation: LY40, p = .033 [0.0025]; LY80, p = .659 [0.0025], MMRM analysis). RIS statistically separated from placebo in both populations (p < .001 [0.05]). There were no statistically significant differences in the incidence of serious adverse events, and no seizures on LY2140023.

Conclusion

LY2140023 treatment did not demonstrate efficacy in populations studied. Overall, LY2140023 treatment was generally well tolerated with no new adverse safety findings compared to previous trials. Further understanding of the role of glutamate as a therapeutic target in schizophrenia is needed.

Clinical trials registration

A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
ClinicalTrials.gov identifier: NCT01086748.
Appendix
Available only for authorised users
Literature
1.
Stone JM, Dietrich C, Edden R, Mehta MA, De Simoni S, Reed LJ, Krystal JH, Nutt D, Barker GJ: Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry. 2012, 17: 664-665. 10.1038/mp.2011.171.CrossRefPubMed
2.
Harrison PJ, Weinberger DR: Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005, 2005 (10): 40-68. 10.1038/sj.mp.4001558.CrossRef
3.
Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, Bear MF, Umbricht D, Hajos M, Potter WZ, Lee CM: Translating glutamate: from pathophysiology to treatment. Sci Transl Med. 2011, 3: 102mr2-10.1126/scitranslmed.3002804. doi:10.1126/scitranslmed.3002804CrossRefPubMedPubMedCentral
4.
Ayalew M, Le-Niculescu H, Levey DF, Jain N, Changala B, Patel SD, Winiger E, Breier A, Shekhar A, Amdur R, Koller D, Nurnberger JI, Corvin A, Geyer M, Tsuang MT, Salomon D, Schork NJ, Fanous AH, O'Donovan MC, Niculescu AB: Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry. 2012, 17: 887-905. 10.1038/mp.2012.37.CrossRefPubMedPubMedCentral
5.
Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H: Glutamatergic (N-Methyl-D-aspartate Receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?. Molecular Pharmacol. 2010, 77: 317-326. 10.1124/mol.109.059865.CrossRef
6.
Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007, 13: 1102-1107. 10.1038/nm1632.CrossRefPubMed
7.
Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, Jackson K, Kryzhanovskaya L, Jarkova N, HBBI Study Group: A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011, 31: 349-355. 10.1097/JCP.0b013e318218dcd5.CrossRefPubMed
8.
Liu W, Downing ACM, Munsie LM, Chen P, Reed MR, Ruble CL, Landschulz KT, Kinon BJ, Nisenbaum LK: Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia. Pharmacogenomics J. 2012, 12: 246-254. 10.1038/tpj.2010.90.CrossRefPubMed
9.
Nisenbaum L, Zhao F, Downing ACM, Munsie LM, Chen P, Fijal B, Smith MR, Millen BA, Adams DH, Kinon BJ: Confirmation of association between genetic markers in 5HTR2A and response to mGLU2/3 agonist LY2140023 monohydrate in schizophrenia. Eur Neuropsychopharmacol, 2011. 2011, 21 (Suppl 3): S243-S244. 10.1016/S0924-977X(11)70375-3.CrossRef
10.
Kay S, Lewis A, Fiszbein A: Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13: 261-276. 10.1093/schbul/13.2.261.CrossRefPubMed
11.
Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R: Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000, 101: 323-329.PubMed
12.
Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry. 1989, 154: 672-676. 10.1192/bjp.154.5.672.CrossRefPubMed
13.
Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970, 212 (Suppl): 11-19. 10.1111/j.1600-0447.1970.tb02066.x.CrossRef
14.
Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised (Publication ADM 76–338). 1976, US Dept of Health, Education, and Welfare, Rockville, Md
15.
Wiens BL, Dmitrienko A: The fallback procedure for evaluating a single family of hypotheses. J Biopharmaceutical Statistics. 2005, 15: 929-942. 10.1080/10543400500265660.CrossRef
16.
Bretz F, Maurer W, Brannath W, Posch M: A graphical approach to sequentially rejective multiple test procedures. Statist Med. 2009, 28: 586-604. 10.1002/sim.3495.CrossRef
17.
Kemp AS, Schooler NR, Kalali AH, Alphs L, Anand R, Awad G, Davidson M, Dubé S, Ereshefsky L, Gharabawi G, Leon AC, Lepine JP, Potkin SG, Vermeulen A: What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?. Schizophr Bull. 2010, 36: 504-509. 10.1093/schbul/sbn110. doi:10.1093/schbul/sbn110CrossRefPubMed
18.
Fedorov VV, Liu T: Enrichment Design. Wiley Encyclopedia of Clinical Trials 2007, 1–8.,
19.
Mallinckrodt CH, Zhang L, Prucka WR, Millen BA: Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacol Bull. 2010, 43: 53-72.PubMed
20.
Khin NA, Chen YF, Yang Y, Yang P, Laughren TP: Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. J Clin Psychiatry. 2012, 43: 53-72.
21.
Adams DH, Kinon BJ, Baygani S, Millen BA, Velona I, Kollack-Walker S, Walling DP: A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry. 2013, 13: 143-10.1186/1471-244X-13-143. doi:10.1186/1471-244X-13-143CrossRefPubMedPubMedCentral
22.
Alper K, Schwartz KA, Kolts RL, Khan A: Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry. 2007, 62: 345-354. 10.1016/j.biopsych.2006.09.023.CrossRefPubMed
Metadata
Title
A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia
Authors
AnnCatherine M Downing
Bruce J Kinon
Brian A Millen
Lu Zhang
Lin Liu
Margarita A Morozova
Ronald Brenner
Tami Jo Rayle
Laura Nisenbaum
Fangyi Zhao
Juan Carlos Gomez
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2014
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-014-0351-3

Other articles of this Issue 1/2014

BMC Psychiatry 1/2014 Go to the issue

Research article

Sleep complaints in adolescent depression: one year naturalistic follow-up study

Research article

Population level mental distress in rural Ethiopia

Research article

Predictors of posttraumatic stress symptoms following childbirth

Research article

Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia

Research article

Clinical predictors associated with full remission versus episode of major depressive disorder outpatients: the experience at a teaching hospital in Taiwan

Research article

Psychiatric stigma and discrimination in South Africa: perspectives from key stakeholders